CMAC’s new CEDAR EPSRC CDT to train 90 PhDs in Cyber-Physical Systems For Medicines Manufacturing
CMAC, a world-leading medicines manufacturing research centre led by the University of Strathclyde in collaboration with our partners at Leeds University, Imperial College London, and Sheffield University, has secured a Centre for Doctoral Training (CDT) grant funded by UKRI to launch the new CEDAR programme. This ground-breaking CDT is set to revolutionise the pharmaceutical and technology sectors by addressing critical skills needs within the industry.
Developed in collaboration with industry partners, CEDAR will train 90 future leaders with the multidisciplinary skills essential for advancing next-generation, sustainable medicines manufacturing. By developing novel Cyber-physical systems that harness the power of digital technologies including artificial intelligence, robotics and augmented reality, CEDAR will deliver the talent pipeline of future leaders who can help to bring new medicines to patients, faster, more sustainably and cost effectively.
The CEDAR programme places individual students at its core, providing world-class technical training, impactful research opportunities, and the establishment of a lifelong network of peers, academic faculty, and industry experts. Graduates will embark on transformative research projects aligned with the Industry 5.0 paradigm and develop the way that cyber-physical systems can help make medicines manufacturing more sustainable, resilient and human-centric.
The support and engagement of CMAC Tier 1 Industry partners (AstraZeneca, Pfizer, Takeda, Roche, Chiesi, Lilly, UCB, and Sanofi) as well as an array of other partners in co-developing our CDT approach, have been crucial. They will contribute throughout the delivery of the programme via training, project co-supervision, mentoring and placements, ensuring graduates are exposed to industry challenges and best practices. Students will also benefit from a world class research environment in the award-winning facilities at Strathclyde and our partners. This includes substantial recent investments in our digital and advanced manufacturing technologies made possible by the £33.4M UK RPIF partnership to establish the new CMAC Data Lab.
Click arrows to view quotes.
About CMAC:
CMAC is an internationally leading manufacturing research centre with a unique configuration of academic research, applied, and pre-competitive programmes. Working in partnership with Tier 1, Tier 2, academic, and innovation partners, CMAC's goal is to transform Medicines Development, Manufacture & Supply, and further grow its world-class portfolio of multi-disciplinary collaborative research. This includes the Digital Medicines Manufacturing Research Centre (DM²), Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP), UKRPIF Net Zero Pilot, UKRPIF CMAC Data Lab, and the CMAC Future Manufacturing Research Hub, along with training and translation projects within a world-class facility.
Valued partners include:
